Clinical performance of AI-integrated risk assessment pooling reveals cost savings even at high prevalence of COVID-19

Farzin Kamari,Esben Eller,Mathias Emil Bøgebjerg,Ignacio Martínez Capella,Borja Arroyo Galende,Tomas Korim,Pernille Øland,Martin Lysbjerg Borup,Anja Rådberg Frederiksen,Amir Ranjouriheravi,Ahmed Faris Al-Jwadi,Mostafa Mansour,Sara Hansen,Isabella Diethelm,Marta Burek,Federico Alvarez,Anders Glent Buch,Nima Mojtahedi,Richard Röttger,Eivind Antonsen Segtnan
DOI: https://doi.org/10.1038/s41598-024-59068-6
IF: 4.6
2024-04-18
Scientific Reports
Abstract:Individual testing of samples is time- and cost-intensive, particularly during an ongoing pandemic. Better practical alternatives to individual testing can significantly decrease the burden of disease on the healthcare system. Herein, we presented the clinical validation of SegtnanTM on 3929 patients. SegtnanTM is available as a mobile application entailing an AI-integrated personalized risk assessment approach with a novel data-driven equation for pooling of biological samples. The AI was selected from a comparison between 15 machine learning classifiers (highest accuracy = 80.14%) and a feed-forward neural network with an accuracy of 81.38% in predicting the rRT-PCR test results based on a designed survey with minimal clinical questions. Furthermore, we derived a novel pool-size equation from the pooling data of 54 published original studies. The results demonstrated testing capacity increase of 750%, 60%, and 5% at prevalence rates of 0.05%, 22%, and 50%, respectively. Compared to Dorfman's method, our novel equation saved more tests significantly at high prevalence, i.e., 28% ( p = 0.006), 40% ( p = 0.00001), and 66% ( p = 0.02). Lastly, we illustrated the feasibility of the SegtnanTM usage in clinically complex settings like emergency and psychiatric departments.
multidisciplinary sciences
What problem does this paper attempt to address?